Company profile
Kivu Bioscience Inc.
Privately held: no public share price (Private ADC biotech; $92M Series A led by Novo Holdings, Oct 2024. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.biospace.com/press-releases/kivu-bioscience-raises-92-million-series-a-led-by-novo-holdings-to-advance-next-generation-antibody-drug-conjugates]) · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | PTK7 (protein tyrosine kinase 7)Antibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.